Status: Recruiting
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment (TMT) and achieved CR. All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.
Participants needed: 54
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Peking University First HospitalUpdated: Jan 10, 2022Locations: 1
Eligibility criteria
Male/female participants who are at least 18 years of age on the day of signing... [+9]
A WOCBP who has a positive urine pregnancy test within 72 hours prior to. If the... [+18]